STOCK TITAN

Corbus Pharmaceuticals Holdings (CRBP) Stock News, Apr-Jul 2026

CRBP NASDAQ

Corbus Pharmaceuticals Holdings, Inc. reports clinical-stage drug-development news in oncology and obesity. Updates center on CRB-701, a next-generation Nectin-4 antibody-drug conjugate licensed from CSPC Megalith Biopharmaceutical, including data presentations in head and neck squamous cell carcinoma and cervical cancer, FDA interactions and Fast Track designations.

Company news also covers CRB-913, a peripherally restricted oral CB1 inverse agonist for obesity, and CRB-601, an anti-integrin monoclonal antibody targeting TGFβ activation. Recurring items include clinical trial disclosures, medical-meeting presentations, management conference appearances, governance changes and operating or financial results.

Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) reported that the U.S. FDA has cleared initiation of TEMPO-1, a registrational Phase 2 study of CRB-701, a next-generation Nectin-4–targeted antibody drug conjugate, in second-line oropharyngeal squamous cell carcinoma (OPSCC). The randomized controlled trial will enroll approximately 250 patients and compare CRB-701 to investigator’s choice of capecitabine, cetuximab or docetaxel. The primary endpoint is objective response rate to support a potential accelerated approval, with overall survival intended to support potential full approval. Corbus expects to begin enrollment in September 2026.

The FDA decision follows Phase 1/2 data in 2L+ OPSCC at a 3.6 mg/kg dose, where CRB-701 achieved a confirmed objective response rate of 42.9%, median duration of response of 6.3 months, and median progression-free survival of 5.6 months (ongoing). OPSCC is estimated to represent about half of U.S. second-line head and neck cancer cases, with roughly 14,000 patients annually eligible for 2L treatment and about 7,000 deaths. CRB-701 has two FDA Fast Track designations in head and neck squamous cell carcinoma and cervical cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
-
Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) appointed Leonardo Viana Nicacio, M.D. as Chief Medical Officer. He brings over 20 years of oncology experience, including leadership roles at Seagen, Stemline, AstraZeneca and Protara.

Corbus plans to initiate the TEMPO-1 registrational CRB-701 study in 2L OPSCC in summer 2026 and expects CANYON-1 CRB-913 obesity data in late summer 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.70%
Tags
none
-
Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ:CRBP) reported updated Phase 1/2 data for CRB-701, a Nectin-4 targeted ADC, in second-line (2L) HPV-associated tumors.

At 3.6 mg/kg, confirmed ORR was 42.9% in 2L OPSCC and 34.4% in 2L cervical cancer, with ongoing median DOR of 6.3 and 8.0 months, and PFS of 5.6 and 4.3 months, respectively. In a 317-patient safety population, discontinuations related to CRB-701 were 2.8%. Ocular AEs occurred in 66.2% of patients, with 12.6% Grade 3 and one Grade 4 case; ocular AE-related discontinuations were 1.9%. Corbus plans a registrational 2L OPSCC trial (TEMPO-1) in summer 2026 and has FDA alignment on randomized study designs in 2L OPSCC and 2L cervical cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.31%
Tags
Rhea-AI Summary

Corbus Pharmaceuticals (Nasdaq: CRBP) appointed former Evercore Managing Director Nishant Saxena as its first Chief Business Officer and scheduled a May 26, 2026 conference call to review updated Phase 1/2 data for Nectin‑4 ADC CRB-701 in HNSCC and cervical cancer.

The company highlighted expected summer 2026 milestones, including initiating a registrational CRB-701 study in second-line HNSCC and completing the 240-patient CANYON-1 Phase 1b study of obesity candidate CRB-913, plus multiple CRB-701 presentations and an HNSCC KOL event at the 2026 ASCO meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.29%
Tags
conferences
-
Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) appointed pharma executive Brent Pfeiffenberger, PharmD, MBA, President and CEO of Century Therapeutics, to its Board of Directors.

He brings extensive oncology commercialization experience as Corbus advances CRB-701 and CRB-913, with key data readouts and a planned CRB-701 registrational study expected this summer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.40%
Tags
management
-
Rhea-AI Summary

Corbus Pharmaceuticals (Nasdaq: CRBP), a clinical-stage company in oncology and obesity, announced that CEO Yuval Cohen will present a corporate overview and hold investor meetings at the RBC Capital Markets Global Healthcare Conference on May 19, 2026, and the Jefferies Global Healthcare Conference on June 4, 2026, both in New York.

Presentations will be webcast. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate targeting Nectin-4-expressing tumors, and CRB-913, an oral, highly peripherally restricted CB1 inverse agonist for obesity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.30%
Tags
conferences
Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ:CRBP) reported Q1 2026 results and pipeline updates in oncology and obesity.

The company recorded a $23.0M net loss and $24.3M operating expenses, with $138.2M in cash expected to fund operations into 2028, while advancing CRB-701 toward registrational studies and completing enrollment in the 240-patient CANYON-1 obesity trial for CRB-913.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.53%
Tags
-
Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) will host an in-person and virtual KOL event at ASCO 2026 to present updated Phase 1/2 data for CRB-701 in head and neck squamous cell carcinoma (HNSCC).

The event is June 1, 2026 at Marriott Marquis Chicago; poster data at ASCO May 29–June 2 will include response durability and subgroup analyses from 75 HNSCC participants. The ongoing three-part study has evaluated CRB-701 in 317 advanced solid tumor participants. According to Corbus, the company recently announced broad alignment with the FDA on a registration path for CRB-701 in HNSCC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
none
-
Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) announced that updated Phase 1/2 clinical data for CRB-701, a next-generation Nectin-4 ADC, will be presented at ASCO 2026 May 29–June 2 in Chicago.

Presentations include an oral session for cervical cancer (May 29) and a poster for HNSCC (May 30). Abstracts post on May 21, 2026. Corbus expects to start a registrational study in second-line HNSCC in mid-2026 and to report CRB-701 plus Keytruda combination data in Q4 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.80%
Tags
Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) announced the Last Patient First Visit in its CANYON-1 Phase 1b study of CRB-913 for obesity on April 14, 2026. The 16-week, double-blind, placebo-controlled, dose-ranging trial enrolls 240 obese, non-diabetic participants across 20 mg, 40 mg, and 60 mg cohorts.

The study is on track for completion in summer 2026, with participants dosed for three months and monitored one month post-dosing; Phase 1b will build on Phase 1a weight-loss signals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
none

FAQ

What is the current stock price of Corbus Pharmaceuticals Holdings (CRBP)?

Corbus Pharmaceuticals Holdings (CRBP) last closed at $2.75.

What is the market cap of Corbus Pharmaceuticals Holdings (CRBP)?

The market cap of Corbus Pharmaceuticals Holdings (CRBP) is approximately $56.6M.